🌟 Call for attendees to the CRISPRMED25 Workshops! 🌟
Dear GenE-HumDi Members,
We support early career and young researchers in the field of therapeutic Gene Editing. For this reason, we are very excited to announce that we will be supporting selected young members attending the CRISPRMED25 Conference and enrolled in the CRISPRMED25 Workshops, co-organized by GenE-HumDi (COST action CA21113) and CRISPR MEDICINE NEWS (CRISPRMED). as part of the CRISPRMED25 Conference.
📌 Workshop Topics:
CRIPRMED25 Workshops:
Tools: Choosing the Right Gene-Editing Approach
Delivery: Navigating the CRISPR Delivery Landscape
Safety: Pre-Clinical Safety Analyses
💶 Financial Aid Includes:
Long-distance travel support to/from the venue*
Daily allowance for the workshop*
*Long-distance travel expenses up to 500.00€ and daily allowance will be reimbursed according to the approved budget and will abide by COST rules and regulations.
📝 How to Apply: Interested attendees must apply soon:
Send an email to the Grant Holder Manager (raquel.soriano@juntadeandalucia.es) indicating the state of your application for the workshop and providing your chosen topic.
Include in the email a letter of interest, of no more than 1,000 words addressed to the Grant Award Coordinator. Please include:
A contact e-mail address if different from your COST contact.
Your current position
Whether you are an active member in any GeneHumdi WG
List your contributions to GeneHumdi initiatives (meetings, white papers, peer-reviewed papers, etc, …)
How does your work/research/interest align with the workshop topics?
How attending will benefit their current position or future perspectives?
📅 Deadline: March 27th Applications must be submitted by this date to allow the resolution of grants before April. Active young members will be given priority, and applicants shortlisted by the Grant Award Coordinator will be notified shortly after.
Don’t miss this opportunity to enhance your knowledge and network with experts in the field!
For questions or to submit your application, contact the Grant Holder Manager at raquel.soriano@juntadeandalucia.es.
2023-2024 period has been fruitful with many steeps and networking connections getting us closer to our objectives. This reports are just proof!
Two years ago, COST Action CA21113 was given green light and we started this adventure of seeking for members willing to help us build an European network aiming to make Genome Editing for the treatment of Human Disease a reality.
We have now reach half of the action’s lifespan and is a great moment to reflect on the achievements and contribution of the academic and industry researchers, Advance Medicine technicians and engineers, Healthcare professionals, Scientific Divulgators, Regulatory and patient advocacy groups.
We are very proud of the hard work of volunteers, and the commitment of young talent to help GeneHumdi initiatives.
Today we wanted to compile some of the recent achievements in this post entry, to pay tribute to the good work of the volunteer members. During this 2 years we had to rethink our structure and embrace in a single WG the interest of industry a regulatory actors, leaving the action with the following structure:
WG2 – Improvement of GE technology
WG3 – Delivery Strategies
WG4 – Safety issues: Monitoring and standardization
WG5 – Translation into the clinic
WG6 – Technology transfer and industry / Regulatory issues
WG7 – Dissemination
This structure is helping both advancing within the focused scope of the WG and also nurturing collaborative works that materialized the following COST Action achievements:
Genome Editing tools Reference Document
WG2 – Improvement of GE technology, led by Rasmus O. Bak presented the network with a reference document with an overview of Genome Editing tools and members’ interests within our COST action network
Reference WG2 Document including efficacy, specificity and catalogue of producers of the available endonucleases independent GE tools.
GeneHumdi consensual hand-book on cells types where furtherimprovements are required to achieve efficient and specific GE.
This has been expanded to the realization of actual Training Schools to instruct younger scientist and future industry leaders into the use of genome editing tools
Standardized procedure protocols for the determination of off-target for experimentaluse in preclinical and clinical studies
Fruit of interactions between members from different Working Group members, GenE-HumDi COST action is nourishing collaborative works, and the Scientific articles produced by Members are Proof:
Summary of the SEcond Period General Meeting held in Limassol , Cypryus
During our second general meeting we engaged EU genome editing leaders in Limassol in a collaborative meeting . This Meeting was instrumental for the materialization of collaborations that are yielding scientific revision on genome editing and to promote the capabilities of young researchers in our network.
Guidelines and reflections concerning regulatory aspects of new gene editing tools
Technology transfer, industry and regulatory issues working group, leaded by Carsten Lederer, have recently shared a great reference document elaborated by WG6 members. The Full text is openly available.
WG6 – Technology transfer and industry / Regulatory issues Reference Document.
Originally drafted by the action SCC, Fco. Javier Molina, and former WG7 leader, Luís Montoliu. And approved by MC members, the plan describes the methods and protocols for the liaison between networks members, working groups and external stakeholders.
Booklet summarizing all the main conference of each WG during the half-life of the action
This a great moment in the Actions life to reckon on the progress of the network activity. We have elaborated a proceeding booklet summarizing all the main conference of each WG during the half life of the action. This detailed summary of the WG records is helping us to learn from the many successes achieved and identify areas that will need further attention in the upcoming years of the network
Summary of state of the art concerns and opportunities for Genome Editing in the Medical Field.
During our Kick-off Meeting we manage to gather European leaders. Our call is still open to all different gears involved in the research, translation, experimental medical application, medical approval and healthcare access and patient advocacy. But our scope is fixed in making Genome editing technologies an actual medical option.
GenE-HumDi Workshop in Barcelona, 3-4 October 2024
UPDATE 23/09/2024: FINAL PROGRAM AVAILABLE! Registration for students, early career Scientist and Young Professionals is open. Secure your seat today: Showcase your research and network with field leaders: Poster a short-talk opportunities !
Genome editing tools and their delivery systems are advancing quickly, but they rely on each other to improve genome editing methods. This meeting will showcase the latest developments in both areas and foster connections and collaborations among scientists to boost the effectiveness of their research projects.
This is open event organized by Genome Editing for the treatment of Human Disease ( GeneHumdi| COST action 21113). A network committed to foster therapeutic genome editing therapeutic by nourishing collaborative networks and promoting early career scientist and industry engagement with the field. In this Workshop we will:
1. Identify and evaluate the existing endonuclease-independent platforms (EIP) and their potential uses in various applications.
2. Identify and evaluate the existing endonuclease-dependent platforms and their potential uses in various applications.
3. Create a comprehensive overview of the current delivery methods used for genome editing (GE) in various cell types for clinical applications.
4. Create a comprehensive overview of the current delivery methods used for in vivo genome editing (GE) in different animal models and clinical environments
This workshop is made possible thanks to a collaboration of GenE-Humdi and IDIBELL. We are thrilled to announce that several field leaders are now confirmed speakers:
Dr. Marc Güell (Pompeu Fabra University, Spain)
Dr. Vittoria. Raffa (Associate Professor in Molecular Biology, Ph.D. in Nanotechnology, M.Sc. in Chemical Engineering, Italy)
Dr. Giedrius Gasiunas (Caszyme, Lithuania)
Dr. Peng Ling (Aix-Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille, France)
Dr. Julian Cerón Madrigal (Institut d’Investigació Biomèdica de Bellvitge, Spain)
Dr. Karen O´Hanlon Cohrt (CRISPR Medicine News, Denmark)
Dr.Alessia Cavazza (UCL, UK)
Dr. Fco Javier Molina Estévez (GENyO, Spain)
Dr. Laura Batlle Morera (CRG, Barcelona)
Dr. Benabdellah Karim (GENyO, Spain)
Dr. Gloria Gonzalez Aseguinolaza (DNA & RNA Medicine Division, Gene Therapy for Rare Diseases Department, Center for Applied Medical Research (CIMA), University of Navarra, IdisNA, Spain).
Dr.Cecilia Jiménez-Mallebrera (Neuromuscular Unit. Institut de Recerca Sant Joan de Deu. Hospital Sant Joan de Déu Barcelona, Spain).
Dr. Mariana Köber (Biomedical Research Network on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain)
Dr.Carles J. Ciudad (Universitat de Barcelona, Spain)
Dr. Jan Gorodkin (Department of Veterinary and Animal Sciences, Center for non-coding RNA in Technology and Health, University of Copenhagen, Denmark.).
Venue: Residencia de Investigadores del CSIC
Carrer de l’Hospital, 64, Ciutat Vella, 08001 Barcelona
Two Days Packed with Science: Thursday October 3rd( 2:00 pm to 8 pm ) and Friday October 4th(9:00 am to 15 pm), 2024.
Free attendance: Registration is needed as space is limited to maximize networking. Signature control will be required and assistance certificates will be available upon request.
To register as attendee or presenter, fill the form and send it to GeneHumdi Grant Holder Manager (raquel.soriano@juntadeandalucia.es)Before September 15th!
Organizing committee and contacts: Dr. Julian Cerón Madrigal Dr. Francisco Martin Molina Dr. Karim Benabdellah Dr. Fco Javier Molina Estevez GHM: Raquel Soriano e mail: raquel.soriano@juntadeandalucia.es
2024.09.08 UPDATE!!!! Applications are closed!! Good luck to all applicants
Great opportunity for younger Genome Editing trainees and early career scientists: #ClinicalApplication Aarhus-GenEHumDi Course September 2024 is coming!
GeneHumdi chair Karim Benabdellah has confirmed the participation of the COST Action CA21113 in the incoming training school “Clinical Applications of In Vivo Gene Editing: Methods, Challenges, and Solutions” in collaboration with the Department of Biomedicine, Aarhus University. It will be held 17th -20th September in Aarhus, Denmark.
The course will be locally organized by esteemed Dr. Yonglun Luo, and Dr. Karim Benabdellah, and will be coordinated by the European COST action “Genome Editing to Treat Human Diseases” (GenE-Humdi; action CA21113), an EU-funded network that connects researchers and innovators across Europe and beyond.
In this course, we investigate into the complex landscape of gene editing within a clinical framework, focusing on the generation of a comprehensive map detailing current delivery methodologies employed for in vivo gene editing across various animal models and clinical scenarios, with some insight for ex vivo studies. The course includes a meticulous comparison of efficacy and specificity data, elucidating the diverse array of gene editing tools administered through different delivery methods within specific tissues and organs of interest
Main Objectives:
1. To become familiar with CRISPR techniques: Participants will gain a thorough understanding of CRISPR technology, including its mechanisms, applications, and potential for genetic modification.
2. To learn about AAV (Adeno-Associated Virus) delivery systems: The course will cover the use of AAV vectors in gene editing, focusing on their design, delivery, especially as Donor template for Gene editing approaches as well for transient endonuclease delivery
3. To explore LNP (Lipid Nanoparticle) systems: Attendees will delve into the principles and applications of LNPs in gene editing, particularly their use in delivering mRNA and other gene editing tools
4. To understand the application of LVs (Lentiviral Vectors): The program will provide insights into the use of lentiviral vectors for gene editing.
5. case studies and practical examples of their use in treating different pathologies such as, cancer (Immunotherapy) Neuromuscular Disorders (NMDs), neurological disorders, and Retinal, Pancreatic, and Cardiac Diseases. Check the full program bellow:
GenEHumDi has also launch an specific call to support Young Researchers and Students willing to expand their abilities attending to this Course. If you qualify to assist the course apply for a GeneHumDi support grant : To qualify for support, APPLICATION PERID IS CLOSED Good Luck to all applicants. We see each other in Aarhus!!
For more info on the Summer School Applications and COST support options, follow us GeneHumdi on the LinkedIn GeneHumdi Page, Twitter @genehumdi or our web updates at www.genehumdi.eu
Great opportunity for younger Genome Editing trainees and early career scientists: GenEHumDi Summer Course 2024 is coming!
GeneHumdi chair Karim Benabdellah has confirmed the.. participation of the COST Action CA21113 in the incoming training school “Comprehensive Understanding of the latest advancements in gene editing delivery methods” in collaboration with the National Institute of chemistry. It will be held this summer June 26-28 in Ljubljana, Slovenia.
The course orchestrates around dissecting efficacy and specificity of cutting-edge genome editing technologies considering the major layers that are needed for the success of clinical genome editing interventions. The syllabus articulates around 3 blocks:
1) NVDM: Non-Viral Delivery Methods.
In which we will learn about efficacy and specificity of genome editing delivery tools. And also, applications across different cell types and approaches in clinical settings.
2) Comparative Analyses of Genome Editing (GE)tools.
Evaluating efficacy and specificity of various genome editing tools. And including the comparison of different delivery methods for optimal outcomes.
3) In Vivo Genome Editing Techniques.
Investigating in vivo genome editing techniques in animal models and clinical scenarios. And assessing efficacy and specificity within specific tissues and organs. Check the full program bellow:
From the Genome Editing for the treatment of human diseases (GeneHumdi, COST CA21113), we are happy to announce that we count with the support and expertise of many members interested and the participation of the action chair Karim Benabdel Lah and SCC F. Javier Molina as coordinators.
Genehumdi has also launch an specific call to support Young Researchers and Students willing to expand their abilities attending this Summer Course. If you qualify to assist the course apply for a genehumdi support grant by filling this form (Link open until May 24th): APPLICATIONS ARE NOW CLOSED Good Luck to all applicants.
AUGUST 2024 UPDATE. Review the Course contents and contributions in the following document:
For more info on the Summer School Applications and COST support options, follow us GeneHumdi on the LinkedIn GeneHumdi Page, Twitter @genehumdi or our web updates at www.genehumdi.eu
We are thrilled to announce a virtual seminar series dedicated to the innovative domains of CRISPR technologies and iPSC-based disease models. Join us to gain insights from experts in gene editing and iPSC modeling.
Seminar Series Highlights:
– Introduction to CRISPR (CRISPR 101)
– Potential of iPSC-Based Disease Models
– Massively parallel CRISPR/Cas gene perturbation
– CRISPR-Based Gene Modulation Techniques
– Strategies for Efficient Gene Editing Delivery
– Immune Modulation via Gene Editing
📅 Dates: 14th – 24th November
⏰ Time: 10:00 AM – 11:00 AM
🔗 Access Link to the Seminars: (will be announced soon)
Expand Your Network!
Alongside the seminar series, we are also launching virtual forums, envisioned as a platform for enthusiasts, experts, and novices alike. Dive into discussions, share your thoughts, and pose questions. Let’s build a thriving community centered on the transformative potential of gene editing and its clinical applications.
COST (European Cooperation in Science and Technology) is a funding organisation for research and innovation networks. Our Actions help connect research initiatives across Europe and beyond and enable researchers and innovators to grow their ideas in any science and technology field by sharing them with their peers. COST Actions are bottom-up networks with a duration of four years that boost research, innovation and careers.
